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Introduction: The standard diagnostic method for echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma recep-
tor tyrosine kinase translocation is fluorescence in situ hybridization 
(FISH). Recently, immunohistochemistry (IHC) has been reported 
as a potential method in screening for anaplastic lymphoma kinase 
(ALK)-positive non–small-cell lung carcinomas (NSCLC), whereas 
several authors have reported a discordance between FISH and IHC 
results. We investigated the heterogeneity of ALK gene rearrange-
ment in excision specimens by FISH and also examined whether the 
FISH score of ALK gene rearrangement corresponded in excision 
and biopsy samples from the same patient.
Methods: Twenty ALK IHC-positive patients including six patients 
treated with crizotinib therapy were evaluated for the presence of 
ALK FISH. For evaluation of heterogeneity of ALK gene rearrange-
ment in excision specimens, we defined six to 10 observation areas 
in each case, and the number of ALK FISH positive observation areas 
(≥15% rearrangement detected) was investigated. ALK FISH score 
in small biopsy samples was classified as positive (≥15% rearrange-
ment detected), equivocal (5–14% rearrangement detected), or nega-
tive (<4% rearrangement detected).
Results: Of a total of 64 tumor observation areas from nine excision 
specimens, 50 areas were positive for ALK gene rearrangement (81.8%). 
In the comparison of excision and small biopsy samples, all excision 
specimens were ALK FISH-positive (100%; 6 of 6), whereas only three 
of the small biopsy samples in these patients were positive (50%; 3 of 6), 
two were equivocal (33%; 2 of 6), and one was negative (17%; 1 of 6). 
The two equivocal patients received crizotinib and showed a response.
Conclusion: ALK gene rearrangement heterogeneity was observed 
in NSCLC specimens by FISH. Our findings suggested that IHC-
positive/FISH-equivocal cases should not be considered true “false-
negatives” when a small biopsy sample was used for ALK analysis.
Key Words: Anaplastic lymphoma kinase, In situ hybridization, 
Immunohistochemistry, Crizotinib, Biopsy sample.
(J Thorac Oncol. 2015;10: 800–805)
Anaplastic lymphoma kinase (ALK) gene rearrange-ment with echinoderm microtubule-associated pro-
tein-like 4-anaplastic lymphoma receptor tyrosine kinase 
(EML4-ALK) translocation has been described in a subset 
of patients with non–small-cell lung carcinomas (NSCLC), 
along with several other translocation events, such as TFG-
ALK and KIF5B-ALK.1,2 This genetic rearrangement occurs 
in 2% to 7% of NSCLC patients, predominantly in younger 
individuals with adenocarcinoma who are never-smokers or 
light smokers.3,4 ALK gene rearrangements in NSCLC pro-
vide the basis for targeted therapy with crizotinib and other 
specific ALK inhibitors,5 and the clinical efficacy of the ALK 
inhibitor crizotinib has been demonstrated in ALK fusion-
positive NSCLC.
Fluorescence in situ hybridization (FISH) is the stan-
dard method for detecting ALK rearrangements in NSCLC 
patients.6 Although FISH is regarded as the “standard pro-
cedure” for detection of rearrangements, it is technically 
demanding, expensive, and requires the scrutiny of large num-
bers of individual cells by a highly experienced diagnostician. 
The use of ALK immunohistochemistry (IHC) has been pro-
posed for the screening of patients.7 In recent years, Cabillic 
et al.8 reported that a single FISH or IHC analysis performed 
alone would have failed to detect approximately one-fourth 
of the ALK-positive cases in a large-scale parallel FISH and 
IHC study of ALK status. Although several authors reported 
that ALK IHC is a highly sensitive method with a significant 
correlation with ALK FISH,9,10 the discordance of FISH and 
IHC in ALK status was also shown using samples of excision 
specimen, biopsy, transparietal punch, and liquid.7
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In this study, we investigated the heterogeneity of ALK 
gene rearrangement in excision specimens by FISH and also 
compared the FISH score of ALK gene rearrangement between 
excision and biopsy samples in the same patients.
MATERIALS AND METHODS
Clinical Samples
Diagnostic records at the Kurume University Hospital 
from 2001 to 2014 were reviewed to identify patients with 
a diagnosis of NSCLC that tested positive for ALK IHC. 
Paraffin-embedded blocks from a total of 20 patients (26 
specimens consisting of 11 biopsies and 15 excisions) were 
retrieved (Table 1). Of these patients, six patients received 
crizotinib treatment. This study conforms to the tenets of the 
Declaration of Helsinki and was approved by the Institutional 
Review Board of Kurume University Hospital.
Immunohistochemistry
Paraffin-embedded tissue samples were cut at 4 μm 
and examined on a coated slide glass. Immunostaining with 
ALK antibody (×200, D5F3, Cell Signaling Technology, 
Inc., Danvers, MA) was performed on a fully automated 
Bond-Max system using onboard heat-induced antigen 
retrieval with ER2 for 20 minutes and a Refine polymer 
detection system (Leica Microsystems, Newcastle, United 
Kingdom). Diamino benzidine was used as the chromogen 
in all these immunostainings. The cell line H2228 was used 
as a positive control.
FISH for ALK Rearrangement
Unstained 4-μm paraffin-embedded tissue samples 
were put through deparaffinization and protease pretreat-
ment steps before being denatured and hybridized overnight 
with the ALK break-apart probe (Vysis LSI ALK Dual Color, 
break-apart rearrangement probe; Abbott Molecular, Abbott 
Park, IL) according to manufacturer’s instructions. Tissue 
sections then underwent saline-sodium citrate washes and 
were mounted in 4′,6-diamidino-2-phenylindole for nuclei 
counterstaining.11,12
Evaluation of ALK Gene Rearrangement
Figure 1 shows representative examples of ALK FISH-
positive (split or single orange) and ALK FISH-negative 
(fused or single green) patterns. Evaluation of the signal was 
done according to the Vysis protocol. The ALK probe con-
sists of one orange (telomeric flank) and one green (centro-
meric flank) signals. Adjacent orange and green signals that 
are less than two signal diameters apart or are overlapping 
are considered as one whole fused signal. Splitting of the 
orange and green signals into two or more signal diameters 
apart indicates ALK gene rearrangement. Positive signals 
were considered as follows: orange and green signals are 
separated by more than twice the size of an isolated signal or 
TABLE 1.  Summary of Patient Data
Patient Age Sex Biopsy Excision ALK IHC TKI
1 73 F NS AD Positive
2 52 M NS AD Positive
3 71 F NS AD Positive
4 75 F NS AD Positive
5 53 M NS AD Positive
6 53 F NS AD Positive
7 55 M NS AD Positive
8 33 F NS AD Positive
9 55 M NS AD Positive
10 69 F AD ADSQ Positive
11 58 F AD AD Positive
12 74 F AD AD Positive 
13 56 F AD AD Positive
14 69 F AD AD Positive
15 70 F AD AD Positive Yes
16 62 F AD NS Positive Yes
17 38 F AD NS Positive Yes
18 51 F AD NS Positive Yes
19 57 F AD NS Positive Yes
20 65 F AD NS Positive Yes
NS, no sample; AD, adenocarcinoma; ADSQ, adenosquamous carcinoma; TKI, 
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a single orange signal without a corresponding green signal, 
along with a fused signal, indicates loss of the green frag-
ment. Negative signals were considered follows: orange and 
green signals overlap or are separated by less than twice the 
size of an isolated signal or a single green signal without 
a corresponding orange signal, along with a fused signal, 
indicates loss of the orange fragment. Nuclei with one iso-
lated signal were considered as uninformative. Signals were 
counted in at least 50 evaluable tumor nuclei for each exami-
nation in excision and biopsy specimens by each observer, 
and the number of abnormal cells was summed for determi-
nation of FISH status.
For evaluation of heterogeneity of ALK gene rearrange-
ment in excision specimens, we defined six to ten observa-
tion areas in each case, and the number of ALK FISH-positive 
observation areas (≥15% rearrangement detected) was inves-
tigated in all cases (patient 1–9). In ALK FISH score in small 
biopsy samples, a patient was considered positive for ALK 
rearrangement if ≥15% of cells showed split signals and was 
also considered “equivocal” for ALK rearrangement if 5% to 
14% of cells showed split signals. All FISH analyses were 
evaluated by two experienced observers (H.A. and Y.T.) who 
were unaware of the conditions of the patients.
RESULTS
Heterogeneity of ALK Gene 
Rearrangement by FISH
All samples were successfully examined by ALK IHC 
(D5F3 clone) and ALK FISH (Fig. 2). We first examined the 
heterogeneity of ALK gene rearrangement using excision 
specimens from patients 1 to 9 (Table 2). Patients 1, 5, 7, and 
9 were positive in six of six tumor observation areas (100%; 
6 of 6), whereas patient 8 was positive in only 4 of 8 tumor 
observation areas (50%; 4 of 8). In a total of 64 observation 
tumor areas, positive ALK gene rearrangement was observed 
in 50 areas (81.8%).
Comparison of ALK Gene Rearrangement 
Between Biopsy and Excision Specimens
We next compared FISH scores of ALK gene rear-
rangement in biopsy and excision specimens from the same 
patients (patient 10–15; Table 3). All excision specimens from 
patients were FISH-positive (100%; 6 of 6). In biopsy, three 
FISH-positive patients (50%; 3 of 6) showed greater than 15% 
cells with ALK gene rearrangement. Two patients (33%; 2 of 
6) were classified as equivocal with 5% to 14% cells of ALK 
gene rearrangement. One patient (17%; 1 of 6) was negative 
by FISH because ALK gene rearrangement was only 2% in 
cancer cells (Fig. 3).
ALK FISH in Small Biopsy Sample and 
Patient Response to Crizotinib
We finally evaluated advanced patients who received 
crizotinib. With the exception of patient 15, advanced 
patients (patients 16–20) were not able to undergo surgi-
cal resection of the primary lung cancer; however, ALK 
IHC showed strongly positive in the small biopsy samples 
(Table 4). In FISH, four patients were ALK FISH-positive, 
two were equivocal, and none were ALK FISH-negative. 
Two patients who were IHC-positive/FISH-equivocal 
received crizotinib and showed a response. In Figure 4, one 







(≥ 15%) with 
ALK Gene 
Rearrangement Observation Area Average (%)
1 6 6 100.0
2 5 6 83.3
3 5 6 83.3
4 6 10 60.0
5 6 6 100.0
6 6 10 60.0
7 6 6 100.0
8 4 8 50.0
9 6 6 100.0
50 64 81.8









13 Equivocal (8%) Positive
14 Negative (2%) Positive
15 Equivocal (9%) Positive
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DISCUSSION
Approximately 70% of patients with NSCLC are diag-
nosed at a late stage of disease and are not candidates for 
surgical resection of the primary lung cancer. Indeed, EgFR 
mutation status and/or ALK status testing is required with 
increasing frequency on small biopsy samples including 
cytology samples. Although ALK lung cancers have distinc-
tive morphologic features, with signet ring cells showing a 
significant association with ALK gene rearrangement, mor-
phologic screening alone could not detect a minority of ALK 
lung cancers.11,13 The standard procedure for testing for the 
EML4-ALK translocation is FISH.6 In the clinical setting, 
we sometimes experience “false-positive” ALK lung cancer 
patients who were positive for IHC analysis and negative for 
FISH analysis in small samples, but not in surgically resected 
samples, suggesting that heterogeneity of ALK gene rear-
rangement in ALK lung cancer might exist in ALK-positive 
lung cancer. Therefore, we investigated the heterogeneity of 
ALK gene rearrangement in excision specimens by FISH and 
also compared the FISH score of ALK gene rearrangement 
between excision and biopsy samples from the same patient. 
In this study, we found intratumoral heterogeneity of ALK 
gene rearrangement in ALK lung cancer and a discordance 
of FISH score of ALK gene rearrangement between biopsy 
and excision samples. Indeed, our NSCLC patients who had 
lower scores (equivocal) for ALK gene rearrangement showed 
a tumor response after treatment with crizotinib, an ALK tyro-
sine kinase inhibitor.
Camidge et al.14,15 reported that intratumoral ALK 
gene rearrangement heterogeneity is a reflection of FISH 
assay technique, not biological factors. The heterogeneity of 
ALK gene rearrangement may be associated with the three-
dimensional distribution of tumor cells in histology sections 
in which the semivertical orientation of tumor cells and/or 
nuclear truncation may hamper identification of break apart 
signals because FISH on conventional cytology, in which 
tumor cells are arranged in a single layer, has been reported 
to have much higher success rates for FISH than histology 
specimens.16 Furthermore, it is known that both sensitivity 
and specificity of ALK FISH assay increase according to the 
increase in the number of fields and cells.14 ALK FISH assay 
using a small biopsy section cannot examine as many fields 
and cells as is the case with excision samples. We suggest that 
the main cause of a discordance of FISH score of ALK gene 
rearrangement between biopsy and excision samples may be 
due to the FISH assay technique because ALK protein was 
diffusely positive for ALK IHC in all samples.
ALK IHC for lung cancer requires the use of enhanced 
detection systems and selection of an antibody rather than the 
detection system used in the diagnosis of anaplastic large-
cell lymphoma. The evaluation of several primary antibodies, 
including clone of ALK1, 5A4, or D5F3, has been performed 
for IHC,10,17 and a variety of signal amplification technologies, 
such as enhanced detection systems or antibody-enhanced 
polymer, have been developed to maximize IHC sensitiv-
ity.2,18 Many studies reported that ALK IHC is a highly sensi-
tive method with a significant correlation with ALK FISH. A 
strong intensity (2+ and 3+ score) seemed to be correlated with 
FISH-positive results (IHC-positive/FISH-positive), and weak 
intensity (1+ score) was mainly found to be FISH-negative.12 
Therefore, IHC has demonstrated potential in screening for 
ALK-positive NSCLC. In recent years, Cabillic et al.8 reported 




















Patient ALK FISH in Biopsy Clinical Response
15 Equivocal (9%) Yes
16 Positive Yes
17 Positive Yes
18 Equivocal (6%) Yes
19 Positive Yes
20 Positive Yes
ALK, anaplastic lymphoma kinase; FISH, fluorescence in situ hybridization.
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IHC-positive/FISH-positive in 150 ALK lung cancers analyzed 
from 3244 NSCLC, and the specimens with discordant IHC/
FISH analyses were IHC-negative/FISH-positive (24.0%; 36 
of 150) or IHC-positive/FISH-negative (12.6%; 19 of 150). 
Together, detection of ALK protein and ALK gene rearrange-
ment causes “false-negative” cases for each method.
In our experience, most ALK IHC cases displayed rela-
tively homogenous staining, whereas some cases show definite 
heterogeneous staining. It is well known that adenocarcinoma 
often shows a heterogeneous feature even in the same nodule. 
Although various histologic patterns were observed, mucinous 
cribriform pattern, solid signet ring cell pattern, and papillary 
pattern with mucin production were predominant in our series. 
These histologic patterns are known to be frequently observed 
in adenocarcinoma with ALK rearrangement. When we exam-
ined the correlation between histologic pattern and ALK 
rearrangement of FISH, no apparent correlations were 
observed. Indeed, even areas showing the same histologic fea-
ture did not always show the same result of distribution of ALK 
rearrangement by FISH. It is suggested that the correlation 
between histologic subtypes and distribution of ALK rearrange-
ment by FISH may be low or none. The cause of the IHC-
negative/FISH-positive discordance might be fixation artifacts. 
It is already known that fixation method is important for accurate 
IHC analysis. In breast cancer, the American Society of Clinical 
Oncology (ASCO) and the College of American Pathologists 
(CAP) issued guidelines to standardize fixation for increased 
human epidermal growth factor receptor type 2 (HER2) test-
ing accuracy.19 Yamashita-Kashima et al.20 reported that delay 
before formalin fixation after tissue collection and extended 
fixation time affects IHC analysis.20 Nonbuffered formalin or 
high concentrations of neutral buffered formalin may also affect 
IHC. In FISH, they also described that prolongation of fixation 
time did not affect FISH result; however, delay before fixation 
strongly reduced the FISH score. Therefore, 10% neutral buff-
ered formalin is recommended to optimize sample preparation 
conditions for ALK IHC and FISH in lung cancer. The cause of 
IHC-positive/FISH-negative discordance in this study might be 
tumor heterogeneity of ALK rearrangement. To et al. 17 reported 
that fusion transcriptions were detected by reverse transcription 
polymerase chain reaction in ALK IHC-positive cases without 
ALK rearrangement by FISH and confirmed to be EML4-ALK 
variant 1 by direct sequencing. Surprisingly, ALK FISH scores 
of these cases were 3.5% and 2.1%, which is lower than the 
5.0% level, which we considered as “equivocal” and equiva-
lent to “negative” in our study (patient 14). Le Quesne et al.21 
also presented data of biopsy or cytology samples with 10% to 
15% positive ALK rearrangement by FISH, indicating that ALK 
rearrangement may definitely uneven in lung cancer tissue. 
Camidge et al.14 reported that maximum sensitivity and speci-
ficity occur when four or more fields (~60 cells) were counted, 
whereas this method might be difficult in small biopsy samples. 
Therefore, IHC is essential to identify some ALK lung cancer 
cases that would be underestimated by FISH.
In conclusion, we found a discordance in ALK gene 
rearrangement FISH between small biopsy and excision sam-
ples in ALK lung cancer. Although our study is retrospective 
in nature and has a relatively small sample size, our results 
have a clinical application for NSCLC in which the tumors are 
IHC-positive/FISH-equivocal for ALK rearrangement.
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